Filter Your Results




Mutations in the Gene for Muscle Protein Kinesin A Cause of Amyotrophic Lateral Sclerosis

Wednesday, March 21, 2018—As published in today’s issue of the journal Neuron, researchers have identified specific mutations in the kinesin family gene, KIF5A, that cause amyotrophic lateral scl…

Subcutaneous Immune Globulin Approved for Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy

Friday, March 16, 2018—Already approved in 51 countries for some immune deficiencies, subcutaneous immune globulin (IG) (Hizentra; King of Prussia, PA) has now been approved by the Food and Drug Adm…

Positive Results for Phase 2 Proof-of-Concept Study for Congenital and Childhood Onset Myotonic Dystrophy Type 1

Thursday, March 15, 2018—The results of a phase 2 proof-of concept study of AMO-02, an investigational therapy for childhood-onset myotonic dystrophy type 1 were presented at the Muscular Dystrophy As…

Phase I/IIa Clinical Trial of Stem Cell Therapy for Amyotrophic Lateral Sclerosis Begins in Israel

Tuesday, March 13, 2018—Approval has been granted by the Israel Ministry of Health’s Supreme Committee for Kadimastem (NessZiona, Israel) to immediately begin a phase I/IIa clinical trial of th…

Biosimilar Being Developed for Botox

Thursday, March 01, 2018—In a transatlantic collaboration, Mylan N.V. (Pittsburgh, Pennsylvania) and Revance Therapeutics, Inc. (Hertsfordshire, England) have reached an agreement to collaborate on th…

Microglia May Promote Recovery of Motor Neurons in Amyotrophic Lateral Sclerosis

Wednesday, February 21, 2018—In findings published this week in Nature Neuroscience, researchers Krista J. Spiller, Clark R. Restrepo, Tahiyana Khan, and others described creation of a mouse model of amyo…

Results from Phase 2 Trial of Stem-Cell Treatment for Amyotrophic Lateral Sclerosis to Be Presented at American Academy of Neurology 2018

Wednesday, February 07, 2018—Brainstorm Cell Therapeutics Inc. announced that they will present results from the NurOwn phase 2 randomized, double-blind, placebo-controlled study, showing ALSFRS-R subgrou…

Sublingual Formulation of Riluzole Bioequivalent to Tablet Formulation

Tuesday, January 09, 2018—Biohaven announced positive results from its bioequivalence study of BHV-0223, an innovative sublingual formulation of riluzole, currently available as a 50-mg tablet, which i…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.